This month, Biogazelle launches a novel and unique application: mRNA sequencing on human plasma. mRNA sequencing on plasma – or other body fluids – has not yet been offered by …

Jo, congratulations with this amazing achievement of your R&D team at Biogazelle. Tell us, why are you so excited about the work you have done? What we offer today is …

The 'Survival Associated Mitochondrial Melanoma Specific ONcogenic RNA' is a long non-coding RNA that is specifically expressed in malignant melanoma cells, and not in other normal human cells or other …

Exiqon A/S (NASDAQ OMX: EXQ), a leading provider of flexible solutions for RNA analysis, today announced the impressive results of a comparative study on technologies for functional knockdown. The study …

MARLBOROUGH, Mass., Oct. 20, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology …

Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet …

Biogazelle today announced that it has received €1.1M in funding from the agency for Innovation by Science and Technology (IWT) in Flanders to leverage its cancer therapy development program, focused …

Biogazelle has a longstanding track record and internationally recognized expertise in RNA gene expression analysis, with a particular focus on non-coding RNA, such as microRNAs and long non-coding RNAs. Today, …

On October 6, 2014, Biogazelle announced the closure of an investment round with QBIC Arkiv Fund, Foundation Majoie and SOFI to finance its growth (press release available on http://bgzlle.com/2bCDGtm). Today, Biogazelle …

Biogazelle is a Ghent University spin-off company founded in 2007 by prof. Jo Vandesompele and dr. Jan Hellemans. With a proven track record in gene expression studies, Biogazelle is at …